Tensions between Japan and South Korea come as the U.S. and its trading partners are embroiled in a global trade war.Technologyread more
The one-to-eight stock split would mean the current number of ordinary shares — which stands at 4 billion — will increase to 32 billion. It comes ahead of a reported Hong Kong...Asia Marketsread more
Minutes from the Reserve Bank of Australia's monetary policy meeting in July showed the central bank was ready to adjust interest rates if required.Asia Marketsread more
Current and former Tesla employees working in the company's open-air "tent" factory say they felt pressure to take shortcuts to hit aggressive Model 3 production goals,...Technologyread more
China's fiscal spending increased 10.7% in the first six months from a year earlier, the finance ministry said on Tuesday, underlining the government's bid to support the...China Economyread more
Von der Leyen, one of the longest serving ministers in Germany, has tried to woo European lawmakers over the last two weeks.Europe Newsread more
The findings by McKinsey and Company come amid a year-long tariff fight between the U.S. and China, which has spilled into areas such as technology and security.China Economyread more
Microsoft's considerable reach into the corporate world isn't something Slack CEO Stewart Butterfield is very concerned about.Technologyread more
A devastating outbreak of African swine fever that has killed millions of pigs in China is changing attitudes in a country where farm hygiene has often been seen as lax by...Livestockread more
In a closed-door meeting at a Manhattan mansion, executives outlined changes to controversial software that was implicated in two crashes.Aerospace & Defenseread more
President Donald Trump and the RNC are picking up key supporters in the business community who did not back him as a candidate in 2016.2020 Electionsread more
NEW YORK, July 07, 2016 (GLOBE NEWSWIRE) -- Provista Diagnostics, a private company developing and commercializing protein-based diagnostic, prognostic and monitoring tests for cancers affecting women, today announced the signing of 13 agreements with Third Party Administrator (TPA) Networks for coverage of Videssa® Breast.
Videssa Breast is the first protein-based blood test that can improve the accuracy of early breast cancer detection. These agreements with TPA Networks will expand patient access to Videssa Breast at a reduced cost and ensure optimal reimbursement for the test. TPA Networks are organizations that process insurance claims and specific aspects of employee benefit plans. In addition, they are networks of providers who are contracted to provide healthcare services to plan members.
“Currently, our managed care efforts are focused on increasing coverage of Videssa Breast through agreements with third-party networks,” said Joe Eggler, Chief Commercial Officer of Provista Diagnostics. “The signing of these agreements is an important step in our strategy to work with payors and offer the benefits of a simple blood test for breast cancer detection to tens of millions of women nationwide. For women with abnormal or unclear imaging findings, Videssa Breast can help healthcare providers determine if additional follow-up is needed, and reduce the potential for false positives and false negatives.”
Eggler added, “We are excited about the positive response Videssa Breast has received from TPA Networks. Increasing diagnostic clarity with Videssa is not only important in improving care for women, it can also help steer better use of health system resources. This is particularly helpful in reducing benign biopsies and the burden of false positives on women presented with abnormal or difficult-to-interpret mammography results.”
About Videssa® Breast
Videssa® Breast is the first protein-based blood test of its kind to provide early and accurate detection of breast cancer. In women who present with abnormal or difficult-to-interpret mammography results, the decision whether to order additional imaging or biopsy can be difficult. With a simple blood draw, Videssa Breast can help guide further diagnostic procedures or provide assurance that the patient does not have breast cancer. Videssa Breast transforms the breast cancer detection paradigm and brings clarity to imaging results. When used in combination with imaging, Videssa Breast improves diagnostic accuracy and provides greater confidence and clarity when clinical assessment is challenging.
Provista Diagnostics is a privately held molecular diagnostics company focused on developing and commercializing a new generation of proprietary blood-based proteomic diagnostic, prognostic and monitoring tests designed to address the unmet needs in women’s cancer, such as breast and gynecologic cancers. Provista Diagnostics’ state-of-the-art, high-complexity clinical laboratory is accredited by the College of American Pathologists (CAP) and the Clinical Laboratory Improvement Amendments (CLIA).
Additional information about Provista Diagnostics is available at ProvistaDx.com
Information about Provista Diagnostics’ clinical trials is available at ClinicalTrials.gov
Safe Harbor Statement
Statements contained in this communication not relating to historical facts are forward-looking statements that are intended to fall within the safe harbor rule for such statements under the Private Securities Litigation Reform Act of 1995. The information contained in the forward-looking statements is inherently uncertain, and Provista’s actual results may differ materially due to a number of factors, many of which are beyond Provista’s ability to predict or control, including among others, viability and effectiveness of our sales approach and overall marketing strategies, the outcome of development or regulatory review of our products, commercial success or acceptance by the medical community, competitive responses, our ability to raise additional capital, and the ability to successfully file a registration statement with the SEC. These forward-looking statements are subject to known and unknown risks and uncertainties that could cause actual events to differ from the forward-looking statements. Provista operates in a highly competitive and rapidly changing business and regulatory environment, thus new or unforeseen risks may arise. Accordingly, investors should not place any reliance on forward-looking statements as a prediction of actual results. Except as is expressly required by the federal securities laws, Provista undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, changed circumstances or future events or for any other reason.
Susan LaMacchiaProvista DiagnosticsPR@ProvistaDx.com212-202-3174
Source:Provista Diagnostics, Inc.